Monday, March 25, 2013

Theraclone Sciences Snags $14M More

Seattle-based therapeutic antibody developer Theraclone Sciences said this morning that it has raised $14M, in a combination of equity and debt funding. The firm said that $8M of the funding was equity, which came from its existing investors, including ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures, Versant Ventures and Zenyaku Kogyo. The remaining $6M was a venture debt funding, which came from MidCap Financial and Silicon Valley Bank. The equity funding was a Series B extension, bringing that round to $50M in funding. More information »